Sir.—Deferoxamine administration is still necessary in the management of thalassemia and, when used appropriately, it is beneficial in controlling iron overload.1
In the past, the general assumption that deferoxamine treatment was devoid of side effects resulted in a tendency to administer high doses; the reduction of serum ferritin to below 1000 μg/L was considered an objective to pursue with determination.2 However, in a review of the recent data reported in the literature,3-6 Lo Faro et al1 suggested that the side effects (infections, cataracts, visual-field defects, severe vision loss or more subtle signs of visual and auditory neurotoxicity, and slow growth) of this drug are dose dependent. Moreover, Schilirò and Russo7 asserted that normalization of serum ferritin levels in patients with thalassemia should not be the goal of the treatment and that serum ferritin levels three or four times nor
VOLTI SL, GREGORIO FD, SCHILIRÒ G. Acute Changes in Renal Function Associated With Deferoxamine Therapy. Am J Dis Child. 1990;144(10):1069–1070. doi:10.1001/archpedi.1990.02150340011005
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.